Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 5/20 | 0.53 |
| ▸ | CNR2 | P34972 | 7/20 | 0.52 |
| ▸ | CNR1 | P21554 | 4/20 | 0.49 |
| ▸ | ESR1 | P03372 | 4/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6337585 | 0.84 | CNR2 (0.75) | PTPN1CNR2CNR1ESR1ESR2 | |
| SCHEMBL9444750 | 0.83 | CNR2 (0.73) | PTPN1CNR2CNR1ESR1ESR2 | |
| SCHEMBL6335286 | 0.82 | PTPN1 (0.60) | PTPN1CNR2ESR1MAOBMEN1 | |
| SCHEMBL7816066 | 0.79 | CNR2 (0.54) | PTPN1CNR2CNR1LMNARAB9A | |
| SCHEMBL7816703 | 0.76 | CNR2 (0.57) | PTPN1CNR2CNR1 | |
| SCHEMBL11552702 | 0.75 | CNR1 (0.64) | CNR2CNR1ESR1ESR2MEN1 | |
| SCHEMBL11673954 | 0.75 | BCHE (0.59) | CNR2CNR1MAOB | |
| SCHEMBL7817127 | 0.75 | CNR2 (0.61) | PTPN1CNR2CNR1ESR1ESR2 | |
| SCHEMBL6069407 | 0.74 | PTPN1 (0.91) | PTPN1 | |
| SCHEMBL6335387 | 0.74 | PTPN1 (0.68) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6844358-B2 | Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia | WYETH (US) | 2005-01-18 | — | — | US | disclosed |
| US-20040102480-A1 | Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia | WYETH (US) | 2004-05-27 | — | — | US | disclosed |
| US-6509360-B1 | a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia. | WYETH | 2003-01-21 | — | — | US | disclosed |
| CN-1308621-A | Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia | AMERICAN HOME PROD (US) | 2001-08-15 | — | — | CN | disclosed |
| US-6166069-A | Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102480-A1 | Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia | GPR119, INSR, GCKR | PTPN1 1600/4885CNR2 272/4885CNR1 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.